title: Paying for expensive new technologies: Medicare's experiences with recombinant erythropoietin.
authors.affiliation: U.S. Senate, Special Committee on Aging, Washington, D.C. 20510.
authors.forename: J M
authors.initials: JM
authors.lastname: Coster
authors.forename: F
authors.initials: F
authors.lastname: Gianfrancesco
authors.forename: P
authors.initials: P
authors.lastname: Chuldzinski
mesh_terms: D001709:Biotechnology / Q000191:economics; D003365:Costs and Cost Analysis; D004921:Erythropoietin / Q000627:therapeutic use*; D006410:Hematopoiesis; D006801:Humans; D007676:Kidney Failure, Chronic / Q000628:therapy; D006278:Medicare; D011994:Recombinant Proteins; D006435:Renal Dialysis; D014481:United States
chemical_list: D011994:Recombinant Proteins; D004921:Erythropoietin